3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Polycystic Ovary Syndrome
21
Insulin Resistance
5
Obesity
4
Neoplasms
3
Prostatic Neoplasms
2
Motor Activity
2
Menstruation Disturbances
2
Medulloblastoma
2
Infertility
2
Diabetes Mellitus
2
Breast Neoplasms
2
Weight Loss
1
Vitamin D Deficiency
1
Triple Negative Breast Neoplasms
1
Toxemia
1
Thyroid Neoplasms
1
Premature Birth
1
Pregnancy Complications
1
Prediabetic State
1
Pre-Eclampsia
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-DM Stage II High-risk Colorectal Cancer
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Metabolic Syndrome
1
Liver Neoplasms
1
Infertility, Female
1
Hyperinsulinism
1
Hyperandrogenism
1
Interventions
esmolol
1
epigallocatechin gallate
1
contrast agent BR1
1
alpha-Tocopherol
1
Viusid
1
Sonazoid
1
Sodium Chloride
1
Simvastatin
1
Pentoxifylline
1
Metformin
1
Iodides
1
Everolimus
1
Dietary Supplements
1
Catechin
1
Aspirin
1
2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Fibrosis
×
Metformin
×
Clear all
NCT02319200
2017-01-11
METFOVIR
Assistance Publique - Hôpitaux de Paris
Phase 3
Terminated
11 enrolled